OPTINOSE, INC. (NASDAQ: OPTN) Files An 8-K Other EventsItem 8.01 Other Events.
On December 10, 2018, OptiNose, Inc. (the “Company”) issued a press release announcing the enrollment of the first patient in a global clinical trial to evaluate the safety and efficacy of XHANCE® (fluticasone propionate) nasal spray as a treatment for patients with chronic sinusitus. A copy of the press release is attached as Exhibit99.1 to this report and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d)Exhibits
|
Exhibit No. |
Description |
|
99.1 |
Press Release dated December 10, 2018.
|
OptiNose, Inc. ExhibitEX-99.1 2 a20181211firstpatientcs.htm EXHIBIT 99.1 Exhibit Optinose Announces First Patient Enrolled in Clinical Trial of XHANCE for Chronic Sinusitis –Company also announces first patient enrolled in clinical trial of XHANCE for treatment of nasal polyps in pediatric patientsYARDLEY,…To view the full exhibit click here
